Kirby A J, Muñoz A, Detels R, Armstrong J A, Saah A, Phair J P
Johns Hopkins School of Public Health, Baltimore, Maryland.
J Acquir Immune Defic Syndr (1988). 1994 Dec;7(12):1242-9.
The occurrence of Pneumocystis carinii pneumonia (PCP) in human immunodeficiency virus type 1 (HIV-1)-infected individuals with high CD4+ counts indicates poor immunologic function. Thrush and persistent fever, easily recognized clinically, are potential measures of immunocompetence. This analysis establishes the complex interactions of CD4+ count, thrush, and persistent fever to predict the occurrence of PCP. Analyses used 20,632 person visits from 2,568 HIV-1-seropositive homosexual or bisexual men participating in the Multicenter AIDS Cohort Study (MACS). Comprehensive examinations were conducted semiannually, while occurrences of PCP were assessed continuously. The occurrence of thrush and fever increase in frequency as CD4+ levels decrease. The relative hazard of PCP in the presence of thrush compared with the absence of thrush rises (p < 0.05) from 1 for the lowest CD4+ category to approximately 5 in the highest categories. The relative hazard of PCP in the presence of fever compared with the absence of fever is above one (p < 0.05) in all CD4+ categories. No cases of PCP occurred in individuals on PCP prophylaxis with CD4+ counts > 200/mm3. These results suggest that HIV-1-related symptoms provide a measure of failing immune function that is not reflected by enumeration of CD4+ lymphocytes alone and support the United States Public Health Service recommendation that symptomatic individuals with CD4+ counts > 200/mm3 should be considered for PCP prophylaxis.
在1型人类免疫缺陷病毒(HIV-1)感染且CD4+计数较高的个体中发生卡氏肺孢子虫肺炎(PCP)表明免疫功能较差。鹅口疮和持续发热在临床上易于识别,是免疫能力的潜在指标。本分析确定了CD4+计数、鹅口疮和持续发热之间的复杂相互作用,以预测PCP的发生。分析使用了参与多中心艾滋病队列研究(MACS)的2568名HIV-1血清阳性同性恋或双性恋男性的20632人次就诊数据。每半年进行一次全面检查,同时持续评估PCP的发生情况。随着CD4+水平降低,鹅口疮和发热的发生率增加。与无鹅口疮相比,有鹅口疮时PCP的相对风险从最低CD4+类别时的1上升至最高类别时的约5(p<0.05)。在所有CD4+类别中,有发热时PCP的相对风险与无发热相比均大于1(p<0.05)。CD4+计数>200/mm3且接受PCP预防的个体未发生PCP病例。这些结果表明,HIV-1相关症状提供了一种免疫功能衰退的指标,这是仅通过CD4+淋巴细胞计数无法反映的,并支持美国公共卫生服务局的建议,即CD4+计数>200/mm3的有症状个体应考虑进行PCP预防。